Literature DB >> 24854991

The emerging roles of DOT1L in leukemia and normal development.

C M McLean1, I D Karemaker1, F van Leeuwen1.   

Abstract

Methylation of lysines within histone proteins represents a posttranslational modification system that can have profound effects on gene expression. An evolutionarily conserved, but poorly understood, histone methylation mark occurs on lysine 79 on histone H3 (H3K79). The H3K79 methyltransferase, DOT1L, is involved in a number of key processes ranging from gene expression to DNA-damage response and cell cycle progression. Recently, DOT1L has also been implicated in the development of mixed lineage leukemia (MLL)-rearranged leukemia, where mistargeting of DOT1L causes aberrant H3K79 methylation at homeobox genes. As DOT1L is essential for leukemic transformation, small-molecule inhibitors of DOT1L function are an attractive therapeutic target for this type of leukemia. However, in order to develop safe treatments, it is necessary to also understand the biological functions of DOT1L. Here we review the various functions of DOT1L in normal mammalian development. Dot1L knockout is embryonic lethal in mice and is important for processes as diverse as proliferation of mouse embryonic stem cells, induced and natural reprogramming, cardiac development and chondrogenesis. Additionally, while an important role for DOT1L in embryonic hematopoiesis is clear, its role in postnatal hematopoiesis is less so. Establishing the precise function of DOT1L in normal adult hematopoiesis and understanding its mode of action will aid in our understanding of the use of DOT1L as a therapeutic target in MLL-rearranged leukemia.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24854991     DOI: 10.1038/leu.2014.169

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  63 in total

1.  Cooperative and antagonistic interplay between PU.1 and GATA-2 in the specification of myeloid cell fates.

Authors:  Jonathan C Walsh; Rodney P DeKoter; Hyun Jun Lee; Erica D Smith; David W Lancki; Michael F Gurish; Daniel S Friend; Richard L Stevens; John Anastasi; Harinder Singh
Journal:  Immunity       Date:  2002-11       Impact factor: 31.745

2.  Intracardiac fluid forces are an essential epigenetic factor for embryonic cardiogenesis.

Authors:  Jay R Hove; Reinhard W Köster; Arian S Forouhar; Gabriel Acevedo-Bolton; Scott E Fraser; Morteza Gharib
Journal:  Nature       Date:  2003-01-09       Impact factor: 49.962

3.  DOT1L regulates dystrophin expression and is critical for cardiac function.

Authors:  Anh T Nguyen; Bin Xiao; Ronald L Neppl; Eric M Kallin; Juan Li; Taiping Chen; Da-Zhi Wang; Xiao Xiao; Yi Zhang
Journal:  Genes Dev       Date:  2011-02-01       Impact factor: 11.361

4.  Potent inhibition of DOT1L as treatment of MLL-fusion leukemia.

Authors:  Scott R Daigle; Edward J Olhava; Carly A Therkelsen; Aravind Basavapathruni; Lei Jin; P Ann Boriack-Sjodin; Christina J Allain; Christine R Klaus; Alejandra Raimondi; Margaret Porter Scott; Nigel J Waters; Richard Chesworth; Mikel P Moyer; Robert A Copeland; Victoria M Richon; Roy M Pollock
Journal:  Blood       Date:  2013-06-25       Impact factor: 22.113

5.  Requirement for Dot1l in murine postnatal hematopoiesis and leukemogenesis by MLL translocation.

Authors:  Stephanie Y Jo; Eric M Granowicz; Ivan Maillard; Dafydd Thomas; Jay L Hess
Journal:  Blood       Date:  2011-02-25       Impact factor: 22.113

6.  Aldosterone-sensitive repression of ENaCalpha transcription by a histone H3 lysine-79 methyltransferase.

Authors:  Wenzheng Zhang; Xuefeng Xia; Diana I Jalal; Teresa Kuncewicz; William Xu; Gene D Lesage; Bruce C Kone
Journal:  Am J Physiol Cell Physiol       Date:  2005-10-19       Impact factor: 4.249

7.  Methylation of H3-lysine 79 is mediated by a new family of HMTases without a SET domain.

Authors:  Qin Feng; Hengbin Wang; Huck Hui Ng; Hediye Erdjument-Bromage; Paul Tempst; Kevin Struhl; Yi Zhang
Journal:  Curr Biol       Date:  2002-06-25       Impact factor: 10.834

8.  Catalytic site remodelling of the DOT1L methyltransferase by selective inhibitors.

Authors:  Wenyu Yu; Emma J Chory; Amy K Wernimont; Wolfram Tempel; Alex Scopton; Alexander Federation; Jason J Marineau; Jun Qi; Dalia Barsyte-Lovejoy; Joanna Yi; Richard Marcellus; Roxana E Iacob; John R Engen; Carly Griffin; Ahmed Aman; Erno Wienholds; Fengling Li; Javier Pineda; Guillermina Estiu; Tatiana Shatseva; Taraneh Hajian; Rima Al-Awar; John E Dick; Masoud Vedadi; Peter J Brown; Cheryl H Arrowsmith; James E Bradner; Matthieu Schapira
Journal:  Nat Commun       Date:  2012       Impact factor: 14.919

9.  Structure and regulation of the mDot1 gene, a mouse histone H3 methyltransferase.

Authors:  Wenzheng Zhang; Yoshihide Hayashizaki; Bruce C Kone
Journal:  Biochem J       Date:  2004-02-01       Impact factor: 3.857

10.  Disruptor of telomeric silencing-1 is a chromatin-specific histone H3 methyltransferase.

Authors:  Nicolas Lacoste; Rhea T Utley; Joanna M Hunter; Guy G Poirier; Jacques Côte
Journal:  J Biol Chem       Date:  2002-07-03       Impact factor: 5.157

View more
  48 in total

Review 1.  The upstreams and downstreams of H3K79 methylation by DOT1L.

Authors:  Hanneke Vlaming; Fred van Leeuwen
Journal:  Chromosoma       Date:  2016-01-04       Impact factor: 4.316

2.  Regulation of the Dot1 histone H3K79 methyltransferase by histone H4K16 acetylation.

Authors:  Marco Igor Valencia-Sánchez; Pablo De Ioannes; Miao Wang; David M Truong; Rachel Lee; Jean-Paul Armache; Jef D Boeke; Karim-Jean Armache
Journal:  Science       Date:  2021-01-22       Impact factor: 47.728

3.  The development and validation of EpiComet-Chip, a modified high-throughput comet assay for the assessment of DNA methylation status.

Authors:  Todd A Townsend; Marcus C Parrish; Bevin P Engelward; Mugimane G Manjanatha
Journal:  Environ Mol Mutagen       Date:  2017-07-29       Impact factor: 3.216

Review 4.  The molecular mechanics of mixed lineage leukemia.

Authors:  R K Slany
Journal:  Oncogene       Date:  2016-02-29       Impact factor: 9.867

Review 5.  Nuclear metabolism and the regulation of the epigenome.

Authors:  Ruben Boon; Giorgia G Silveira; Raul Mostoslavsky
Journal:  Nat Metab       Date:  2020-10-12

6.  The PZP Domain of AF10 Senses Unmodified H3K27 to Regulate DOT1L-Mediated Methylation of H3K79.

Authors:  Shoudeng Chen; Ze Yang; Alex W Wilkinson; Aniruddha J Deshpande; Simone Sidoli; Krzysztof Krajewski; Brian D Strahl; Benjamin A Garcia; Scott A Armstrong; Dinshaw J Patel; Or Gozani
Journal:  Mol Cell       Date:  2015-10-01       Impact factor: 17.970

7.  Histone demethylase KDM4A and KDM4B expression in granulosa cells from women undergoing in vitro fertilization.

Authors:  Adam J Krieg; Sarah R Mullinax; Frances Grimstad; Kaitlin Marquis; Elizabeth Constance; Yan Hong; Sacha A Krieg; Katherine F Roby
Journal:  J Assist Reprod Genet       Date:  2018-03-14       Impact factor: 3.412

Review 8.  Epigenetic roots of immunologic disease and new methods for examining chromatin regulatory pathways.

Authors:  Ian A MacDonald; Nathaniel A Hathaway
Journal:  Immunol Cell Biol       Date:  2014-12-23       Impact factor: 5.126

9.  Structural Basis of Dot1L Stimulation by Histone H2B Lysine 120 Ubiquitination.

Authors:  Marco Igor Valencia-Sánchez; Pablo De Ioannes; Miao Wang; Nikita Vasilyev; Ruoyu Chen; Evgeny Nudler; Jean-Paul Armache; Karim-Jean Armache
Journal:  Mol Cell       Date:  2019-04-10       Impact factor: 17.970

10.  Functional interdependence of BRD4 and DOT1L in MLL leukemia.

Authors:  Omer Gilan; Enid Y N Lam; Isabelle Becher; Dave Lugo; Ester Cannizzaro; Gerard Joberty; Aoife Ward; Meike Wiese; Chun Yew Fong; Sarah Ftouni; Dean Tyler; Kym Stanley; Laura MacPherson; Chen-Fang Weng; Yih-Chih Chan; Margherita Ghisi; David Smil; Christopher Carpenter; Peter Brown; Neil Garton; Marnie E Blewitt; Andrew J Bannister; Tony Kouzarides; Brian J P Huntly; Ricky W Johnstone; Gerard Drewes; Sarah-Jane Dawson; Cheryl H Arrowsmith; Paola Grandi; Rab K Prinjha; Mark A Dawson
Journal:  Nat Struct Mol Biol       Date:  2016-06-13       Impact factor: 15.369

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.